- Archit Organosys Ltd is fundamentally a specialist chemical manufacturer that turns two volatile raw materials - chlorine and acetic acid - into a family of chloro-acetic acid derivatives that go into everyday painkillers, crop-protection chemicals, and oil-drilling fluids. Established in 1994 and originally named Shri Chlochem Limited, the company was the first in India to deploy an advanced hydrogenation continuous-process plant for these products, and it has since built a second factory and secured REACH permission to sell across all 27 EU member states. The recurring approach is to make a narrow set of high-demand intermediates, sell them to large pharmaceutical and agrochemical manufacturers both in India and abroad, and run a parallel trading desk in related chemicals and imported bulk drugs that broadens the customer relationship without adding manufacturing complexity.
Business segments
A single manufacturing engine, supplemented by a trading desk that extends its market reach - one core chemistry, two routes to the customer.
1. Chloro-acetic acid derivatives: the manufacturing core
The company makes four chlorine-based chemical intermediates that are essential building blocks for ibuprofen, diclofenac, 2,4-D weed-killer, and oilfield drilling fluids - and it was the first in India to run the continuous hydrogenation process that produces them.
- First-mover process advantage - Archit was the first Indian company to use an advanced hydrogenation continuous-process plant for these products, which gives it a head start in process know-how and product consistency that matters to pharmaceutical and agrochemical buyers.
- Four products, many end-markets - the portfolio consists of Monochloro Acetic Acid (MCA), Sodium Monochloro Acetate (SMCA), Chloro Acetyl Chloride (CAC), and Tri Chloro Acetyl Chloride (TCAC), which find their way into pharmaceutical intermediates (for Ibuprofen, Diclofenac, and Aceclofenac), oilfield chemicals used in drilling, the herbicide 2,4-D, surfactants, cosmetics, and pigments.
- Two factories, one expansion cycle - manufacturing runs out of Naroda (Ahmedabad) and Bhavnagar in Gujarat; the Bhavnagar plant was expanded by 6,000 metric tonnes per annum in 2021-22, taking total capacity to 18,000 MT per annum, funded entirely from internal accruals and completed within nine months.
- REACH opens Europe - the company holds REACH permission, so it can market its products in all 27 EU member countries and the European Economic Area, which is a regulatory gate that smaller domestic competitors often cannot pass.
- Lean and owner-run - the three promoter-directors between them hold decades of chemical-manufacturing and trading experience, and the whole operation runs with just 51 employees, which keeps the cost base tight while the directors stay directly connected to customers.
2. Chemical and bulk-drug trading: extending the customer relationship
Alongside its own factory output, the company buys and resells a range of chemicals and imported bulk drugs, which lets it serve more of a customer's needs without adding manufacturing assets.
- A broader shelf for the same buyers - traded goods have included Acid Slurry, J Acid, Acetic Anhydride, and Linear Alkyl Benzene, alongside imported bulk drugs that the company markets in the domestic pharmaceutical supply chain.
- Revenue from by-product channels - the trading activity is a separate revenue stream, while job-work income, export incentives, and revenue from facilitating the sale of chlorine are reported as other operating revenue, together turning a manufacturing by-product into a separate income stream.
- Same customer base, no extra plants - because the trading desk sells to the same agrochemical, pharmaceutical, and cosmetics sectors that buy the company's own manufactured derivatives, it deepens the commercial relationship without the capital commitment of a new factory.
Group structure and partners
The company is promoter-controlled with no subsidiaries - a structure simplified by two recent divestments that returned the focus to the core chemical-manufacturing business.
- No subsidiaries as of late 2025 - the company previously had a wholly owned subsidiary, Archit Life Science Limited (incorporated September 2022 to make ethyl acetate and other solvents), but an 81% stake was sold to promoter-group buyers in June 2023, and a subsequent rights-issue subscription left Archit Organosys with a 17.13% stake as a related-party investment rather than a subsidiary.
- Nano-materials venture exited at cost - a brief partnership in Novel and Nano Xtreme Solutions LLP (formed December 2023 for nano-technology and graphene materials) was unwound in March 2024, with the company retiring as a partner; the LLP was yet to receive subscription money from the subscribers, and the company’s contribution was ₹5.01 lakhs.
- Related-party ecosystem - promoter-linked enterprises including Krishna Orgochem, Archit Advance Materials, Kalindi Impex, and others form a network of related parties with which the company may transact.